Melanoma genomics – will we go beyond BRAF in clinics?
Abstract In the era of next-generation sequencing, the genetic background of cancer, including melanoma, appears to be thoroughly established. However, evaluating the oncogene BRAF mutation in codon V600 is still the only companion diagnostic genomic test commonly implemented in clinics for molecula...
Saved in:
Main Authors: | Justyna Mirek, Wiesław Bal, Magdalena Olbryt |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-09-01
|
Series: | Journal of Cancer Research and Clinical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00432-024-05957-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01) -
Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
by: Jianhao Bai, et al.
Published: (2025-01-01) -
Magnolol induces cell death through PI3K/Akt‐mediated epigenetic modifications boosting treatment of BRAF‐ and NRAS‐mutant melanoma
by: Abdullah Al Emran, et al.
Published: (2019-03-01) -
Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway
by: Xing Luo, et al.
Published: (2025-01-01) -
Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells
by: Ceyda Colakoglu Bergel, et al.
Published: (2025-01-01)